Search

Displaying results 1061 - 1070 of 4233 in total
  1. Drug

    Conjugated estrogens

    go.drugbank.com/drugs/DB00286
    ApprovedInvestigational

    It also presents a large number of unidentified molecules with weak estrogenic activity as well as non-human molecules when it is obtained from pregnant mares urine. … [T475] The conjugated estrogen mixture was approved for marketing in US in 1942 based on the efficacy against certain conditions.

  2. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    [L50336] Thyroid hormones directly regulate lipid metabolism in the liver; thus, impaired thyroid function, such as low serum thyroid hormone levels, is often observed in NAFLD. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD

  3. Drug

    Tideglusib

    go.drugbank.com/drugs/DB12129
    ApprovedInvestigationalWithdrawn

    [A31601] Tideglusib is being developed by the Spanish pharmaceutic company Zeltia group and its current status is withdrawn for the treatment of Alzheimer's disease as of 2012.

  4. Drug

    Azatadine

    go.drugbank.com/drugs/DB00719
    ApprovedWithdrawn

    Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells.

  5. Drug

    Posaconazole

    go.drugbank.com/drugs/DB01263
    ApprovedInvestigationalVet approved

    Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients.

  6. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    [L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and

  7. Drug

    Trihexyphenidyl

    go.drugbank.com/drugs/DB00376
    ApprovedInvestigational

    [L31843] It has largely been replaced by drugs such as [levodopa].[L31843] Trihexyphenidyl was granted FDA approval on 13 May 1949.[L31768]

  8. Drug

    Velpatasvir

    go.drugbank.com/drugs/DB11613
    ApprovedInvestigational

    Since June 2016, Velpatasvir has been available as a fixed dose combination product with [DB08934], as the commercially available product Epclusa. … Both Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV [L852, A19626].

  9. Drug

    Sacubitril

    go.drugbank.com/drugs/DB09292
    ApprovedInvestigational

    Under normal conditions, neprilysin breaks down other vasodilating peptides and also vasoconstrictors such as angiotensin I and II, endothelin-1 and peptide amyloid beta-protein. … Sacubitril's active metabolite, LBQ657 inhibits neprilysin, a neutral endopeptidase that would typically cleave natiuretic peptides such as atrial natriuretic peptide (ANP), brain natriuretic peptide (

  10. Drug

    Corifollitropin alfa

    go.drugbank.com/drugs/DB09066
    ApprovedInvestigational

    Multiple studies and a meta-analysis suggest that corifollitropin alfa is as efficacious as recombinant FSH in terms of live birth rate, ongoing pregnancy rate, as well as clinical pregnancy rate. … Corifollitropin alfa is marketed as Elonva in more than 75 countries [L2272]. Corifollitropin alfa is produced by a method known as ‘recombinant DNA technology’.